

Bacteremia caused by *Paracoccus yeei* in patient with compensated cirrhosis of the liver



Bacteremia por *Paracoccus yeei* en un paciente con cirrosis hepática compensada

Dear Editor,

The patient was a 56-year-old man with a history of type 2 diabetes mellitus and partial hepatectomy and cholecystectomy due to a hepatocellular carcinoma diagnosed two years before. He presented at the emergency department with a three-day history of fever accompanied by chills, generalized joint pain and dyspnea. He had no diarrhea, expectoration, urinary symptoms, or skin lesions, so the working diagnosis was a bloodstream infection with a probable abdominal focus. The sediment was not abnormal, and abdominal ultrasonography ruled out cholelithiasis and bile duct obstruction. Two peripheral blood samples were started, and empirical antibiotic treatment with meropenem was initiated.

Two blood cultures, both aerobic bottles, were positive after 41 h of incubation (BacT/ALERT®, Biomérieux). Direct Gram staining of the blood culture revealed moderate-sized, gram-negative cocci with a characteristic vacuolated appearance (Fig. 1). Blood cultures were transferred to chocolate and blood agar plates and incubated at 37 °C in an atmosphere with 5% CO₂. Two days later, shiny brown, mucoid, non-hemolytic colonies were observed on the plates (Fig. 1). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) identified the bacteria as *Paracoccus yeei* (*P. yeei*) with a score value of 2.212. Bacterial 16S rRNA gene was amplified and sequenced using universal primers 27 F (5'-AGAGTTTGATCMTGGCTCAG-3') and 1492R (5'-TA CCGTTACCTTGTACGACTT-3'). The obtained sequence was compared with data available from GenBank using

BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) and a 99% identity with the *P. yeei* CCGU 32053 16S rRNA sequence was found.

Susceptibility testing was performed using the minimum inhibitory concentration (MIC) microdilution method (Microscan WalkAway, Beckman coulter). As no interpretative criteria have yet been published for *P. yeei*, we followed the *Pseudomonas* spp. EUCAST breakpoints for aminoglycosides, quinolones and piperacillin-tazobactam and PK-PD (Non-species related) EUCAST breakpoints for the rest.¹ The MIC values were as follow (all of them susceptible): piperacillin-tazobactam: ≤8 µg/mL, cef-tazidime: ≤1 µg/mL, cefepime: ≤1 µg/mL, aztreonam: 4 µg/mL, meropenem: ≤1 µg/mL, amikacin ≤8 µg/mL and ciprofloxacin ≤0.5 µg/mL. Although others have reported strains resistant to ciprofloxacin² or to third-generation cephalosporins,³ our strain was sensitive to these antibiotics.

In the days after the initiation of antibiotic treatment, the patient's condition improved and follow-up blood cultures were negative. At discharge, the patient was prescribed ciprofloxacin for two weeks.

P. yeei, which is classified within the family *Rhodobacteraceae*, are gram-negative, obligate aerobic, nonfermenting cocci or coccobacilli with a characteristic vacuolated or O-shaped appearance in Gram staining. Colonies grow after 24 h of incubation on blood and chocolate agar but not on MacConkey agar. Regarding the biochemical profile, it is catalase and oxidase positive and reduce nitrates.⁴

Since the natural habitat of this bacteria has not been fully defined, it is difficult to predict which patients are at risk of infection. In our patient, the diagnosis was oriented toward sepsis due to an abdominal source, although no abdominal focus of infection had been clearly established. Immunosuppression and certain environmental factors play a decisive role in the pathogenicity of this microorganism, although in our case, the patient's liver




Fig. 1. Mucoid colonies of *Paracoccus yeei* isolated on Chocolate agar (A) and Blood agar (B) after 48 h of incubation. Direct Gram stain from the aerobic blood culture bottle revealed Gram negative cocci with characteristic “doughnut-shape” (arrows) (C).

function was adequate and there was no evidence of immunodepression.

Bacterial infections are much more common in patients with cirrhosis than in the general population due to the increased inflammatory response and dysregulation of the immune system.⁵ *P. yeii* is unique within the genus because it has been associated with opportunistic human infections. Most reported cases are infections in immunosuppressed patients, most commonly peritonitis in patients undergoing peritoneal dialysis.^{2,3,6,7} Other reported infections include myocarditis in a heart transplant recipient,⁸ keratitis in patient who used contact lenses,⁹ and septic arthritis.

To our knowledge, only two cases of bacteremia due to *P. yeii* have been reported. In one, the source was bullous lesions⁴; in the other, a patient with decompensated cirrhosis, the source was unidentified but presumably an abdominal focus.¹⁰ Our patient had histologically confirmed cirrhosis, but no clinical, laboratory, or imaging signs of decompensation, despite a prior history of hepatocellular carcinoma. Like some other patients with *P. yeii* infections, he also had diabetes mellitus, a known risk factor for infections.

It is possible that infections caused by *P. yeii* are underdiagnosed due to low clinical suspicion, given the scant reports in the literature and the low a priori pathogenic potential for this microorganism. In addition, its macroscopic appearance with colonies initially resembling those of a coagulase-negative staphylococcus may lead to the misidentification of the strain if no further investigations are performed.

In recent years, the use of new molecular techniques such as MALDI-TOF MS has led to an increase in the identification of little known microorganisms as the cause of infections. The present case of bacteremia due to *P. yeii* confirms the role of this microorganism as a potential source of infection in humans.

Conflict of interest

The authors declare no conflict of interests.

Acknowledgments

The authors would like to thank Dr. Juan José González López (Microbiology Laboratory, Hospital Vall d'Hebron, Barcelona, Spain) for sequencing the bacterial 16S rRNA gene.

Bibliografía

1. EUCAST. The European Committee on Antimicrobial Susceptibility Testing, breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. Available from: <http://www.eucast.org>.
2. Arias MA, Clark J. *Paracoccus yeii* as a cause of peritoneal dialysis peritonitis in the United Kingdom. IDCases. 2019;15:e00486.
3. Wallet F, Blondiaux N, Foy CL, Loiez C, Armand S, Pagniez D, Courcol RJ. *Paracoccus yeii*: a new unusual opportunistic bacterium in ambulatory peritoneal dialysis. Int. J. Infect. Dis. 2010;14:e173–4.
4. Funke G, Frodl R, Sommer H. First comprehensively documented case of *Paracoccus yeii* infection in a human. J. Clin. Microbiol. 2004;42:3366–8.
5. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–33.
6. Sastre A, González-Arregoces J, Romainoik I, et al. *Paracoccus yeii* peritonitis in peritoneal dialysis. Nefrología. 2016;36:445–6.
7. Palamuthasingam D, Tan KS. The first case of *Paracoccus yeii* species infection in Australia causing peritonitis in an APD patient. Nephrology (Carlton). 2014;19:116.
8. Schweiger M, Stiegler P, Scarpatetti M, et al. Case of *Paracoccus yeii* infection documented in a transplanted heart. Transpl. Infect. Dis. 2011;13:200–3.
9. Courjaret JC, Drancourt M, Hoffart L. *Paracoccus yeii* keratitis in a contact lens wearer. Eye Contact Lens. 2014;40:e21–2.
10. Sack J, Peaper DR, Mistry P, Malinis M. Clinical implications of *Paracoccus yeii* bacteremia in a patient with decompensated cirrhosis. IDCases. 2016;7:9–10.

Miguel Aliste-Fernández^{a,*}, Isabel Sanfeliu-Sala^a,
Jordi Sánchez-Delgado^{b,c}

^a Department of Microbiology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain

^b Hepatology Unit, Digestive Diseases Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain

^c Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain

* Corresponding author.

E-mail address: mikel.92af@gmail.com (M. Aliste-Fernández).

<https://doi.org/10.1016/j.eimc.2020.01.013>

0213-005X/ © 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Endocarditis infecciosa por *Aerococcus urinae*



Aerococcus urinae infective endocarditis

Aerococcus spp. son bacterias grampositivas, anaerobias facultativas y con disposición en pares y racimos. Desde que se definió este género en 1938¹ se han ido identificando nuevas especies —*Aerococcus viridans*, *A. sanguinicola*, *A. christensenii*, *A. urinaehominis*, *A. urinaeequi* y *A. suis*—, pero no fue hasta 1992 cuando se definió *Aerococcus urinae* como una nueva especie². *Aerococcus* spp. se encuentran de manera ubicua en el suelo y en el aire³. Es relevante su participación como parte de la flora normal del tracto urinario humano y de la flora oral humana en pacientes en tratamiento con citostáticos⁴. A pesar de ello, *A. urinae* es una causa poco frecuente de infección del tracto urinario (ITU) y la enfermedad invasiva o la bacteriemia son raras (0,5–3 casos/10⁶ habitantes-año). La incidencia global de endocarditis infecciosa (EI) por *A. urinae* es desconocida, pero hasta donde hemos podido saber no se han reportado más de 50 casos⁵.

Varón de 61 años con antecedentes de obesidad, diabetes mellitus tipo 2, hipertensión arterial y dislipemia en tratamiento con enalapril, metformina y gemfibrozilo. Ingresó por neumonía adquirida en la comunidad y durante el ingreso precisó sondaje vesical por retención aguda de orina, sin encontrarse antecedentes urológicos estructurales ni infecciosos previos. Estaba en tratamiento con levofloxacino cuando presentó disnea, mal estado general y fiebre tras 2 días de tratamiento antibiótico. En la exploración física destacó fiebre de 39 °C y soplo sistólico III/VI en foco aórtico. Analíticamente presentó 19.600 leucocitos/ μ l con 85% de neutrófilos y una proteína C reactiva (PCR) de 145 mg/l (valor normal hasta 5 mg/l). Se tomaron hemocultivos y se evidenció el crecimiento de *A. urinae* en dos botellas. El microorganismo fue sensible a los siguientes antibióticos: penicilina (CMI = 0,008 mg/l), ampicilina (CMI = 0,015 mg/l), meropenem (CMI = 0,06 mg/l), vancomicina (CMI = 0,25 mg/l) y rifampicina (CMI = 0,015 mg/l). El ciprofloxacino se catalogó resistente (CMI > 2 mg/l). Se realizaron ecocardiogramas transtorácico y transesofágico, que revelaron dos grandes vegetaciones ancladas a la válvula aórtica. Con el diagnóstico de EI